SCYNEXIS receives $22 million from GSK to resolve MARIO study dispute
Tweet Send to a Friend
SCYNEXIS Inc. (NASDAQ: SCYX) will receive $22 million from GlaxoSmithKline as part of a resolution regarding their disagreement over restarting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
